Shareholders in Shenzhen Neptunus Bioengineering (SZSE:000078) Have Lost 31%, as Stock Drops 5.8% This Past Week
Shareholders in Shenzhen Neptunus Bioengineering (SZSE:000078) Have Lost 31%, as Stock Drops 5.8% This Past Week
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns. We regret to report that long term Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) shareholders have had that experience, with the share price dropping 31% in three years, versus a market decline of about 10%.
作為一名投資者,努力確保你的整體投資組合超過市場平均水準是值得的。但幾乎可以肯定的是,有時你會買入低於市場平均回報率的股票。我們很遺憾地報告這一長期的深圳市海王星生物工程有限公司。(SZSE:000078)股東有過這樣的經歷,股價在三年內下跌了31%,而市場跌幅約為10%。
Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.
鑑於過去一週對股東的態度一直很嚴峻,讓我們調查一下基本面,看看我們能學到什麼。
See our latest analysis for Shenzhen Neptunus Bioengineering
查看我們對深圳海王星生物工程的最新分析
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
雖然市場是一種強大的定價機制,但股價反映的是投資者情緒,而不僅僅是潛在的企業表現。通過比較每股收益(EPS)和股價隨時間的變化,我們可以感受到投資者對一家公司的態度隨著時間的推移發生了怎樣的變化。
Shenzhen Neptunus Bioengineering saw its share price decline over the three years in which its EPS also dropped, falling to a loss. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. However, we can say we'd expect to see a falling share price in this scenario.
在這三年裡,深圳海王星生物工程的股價下跌,每股收益也下降,出現虧損。由於該公司已陷入虧損狀態,很難將每股收益的變化與股價的變化進行比較。然而,我們可以說,在這種情況下,我們預計會看到股價下跌。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
該公司的每股收益(在一段時間內)如下圖所示(點擊查看具體數位)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20230823/0-669ea6990125c6517e7d437ce8865565-0-234a1514e130aec498c9e03a59056b0c.png/big)
Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.
在買賣股票之前,我們總是建議仔細研究一下歷史增長趨勢,可以在這裡找到。
A Different Perspective
不同的視角
While it's never nice to take a loss, Shenzhen Neptunus Bioengineering shareholders can take comfort that their trailing twelve month loss of 9.4% wasn't as bad as the market loss of around 11%. Given the total loss of 4% per year over five years, it seems returns have deteriorated in the last twelve months. Whilst Baron Rothschild does tell the investor "buy when there's blood in the streets, even if the blood is your own", buyers would need to examine the data carefully to be comfortable that the business itself is sound. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 2 warning signs for Shenzhen Neptunus Bioengineering that you should be aware of before investing here.
雖然虧損從來都不是好事,但深圳海王星生物工程的股東們可以感到欣慰的是,他們過去12個月9.4%的虧損沒有市場約11%的虧損那麼糟糕。考慮到過去五年每年4%的總虧損,過去12個月的回報率似乎有所下降。雖然羅斯柴爾德男爵確實會告訴投資者“在街上有血的時候買入,即使血是你自己的”,但買家需要仔細檢查數據,才能確信業務本身是穩健的。我發現,把股價作為衡量企業業績的長期指標是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他資訊。例如,我們發現深圳海王星生物工程的2個警示標誌在這裡投資之前你應該意識到這一點。
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
對於那些想要找到贏得投資這免費最近有內幕收購的不斷增長的公司名單可能就是合適的選擇。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.